Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant

Expanded access is no longer available for this treatment.
Sponsor:
Information provided by:
Novartis
ClinicalTrials.gov Identifier:
NCT00413270
First received: December 18, 2006
Last updated: July 12, 2011
Last verified: July 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: Expanded access is no longer available for this treatment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given